Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Apr 20, 2024 1:41pm
106 Views
Post# 35999625

RE:Accelerated Approval, surrogate endpoints, registration

RE:Accelerated Approval, surrogate endpoints, registration Specialty drugs, which are typically composed of large molecules that need to be injected or infused, as a category, represent roughly 50% of pharma spending today and continues to increase.

The global oncology market size was valued at USD 222.36 billion in 2023 and is poised to grow from USD 242.15 billion in 2024 to USD 521.60 billion by 2033, growing at a CAGR of 8.9% in the forecast period (2024-2033). 

The oncology market is experiencing rapid growth driven by advancements in cancer diagnosis, treatment, and prevention. Oncology, a medical specialty dedicated to addressing cancer, confronts the challenge of abnormal cell proliferation leading to widespread bodily impact. 

Key Takeaway:

  • - Europe is anticipated to be the most opportunistic market during the forecast period.
  • - The cancer treatment segment dominated the oncology market in 2023, garnering a market share of around 57%.
  • - The cancer diagnostic segment has accounted 43% of the total market share in 2023
  • - The hospitals segment dominated the market in 2023 with a revenue share of 69%
  • - Hospital segment is growing at a CAGR of 10.9% from 2024 to 2033.
  • - Breast cancer market was valued at USD 60.23 billion in 2023.
The U.S. oncology market size was valued at USD 74.71 billion in 2023 and is anticipated to reach around USD 180.12 billion by 2033, growing at a CAGR of 9.2% from 2024 to 2033. 

In Europe, the oncology market emerges as a significant opportunity during the forecast period, driven by a substantial cancer burden affecting the population. 

In the oncology market, immunotherapy emerges as the fastest-growing segment, poised for significant expansion during the forecast period. Immunotherapy represents a revolutionary approach to cancer treatment, leveraging the body's own immune system to identify and combat cancer cells effectively. Immunotherapy capitalizes on the advancements in immunology, a branch of science dedicated to understanding the intricacies of the immune system. 


In the oncology market, breast cancer emerges as the most opportunistic segment during the forecast period. Globally, breast cancer remains a significant health concern, causing 670,000 deaths in 2022 alone. 

https://www.biospace.com/article/releases/laxman-dige-precedenceresearch-com/

<< Previous
Bullboard Posts
Next >>